Can These Helper Cells Kill Cancerous Tumours?

A recent study may pave the way for future cancer therapies after findings indicated that a subset of white blood cells, T helper cells, are potentially capable of destroying cancer cells.

Image Credit

The Findings Giving Hope for Cancer Treatment

The University College London (UCL) investigated molecular and cellular mechanisms in their immunotherapy study conducted on mice.

The UCL study was formulated based on prior research from the New York’s Memorial Sloan-Kettering Cancer Center. They found that following immunotherapy, certain CD4+ T cells transform into cytotoxic cells, at which point they can engage with cancerous cells and kill them. The crux of the latest research has been to identify the way in which this mechanism is initiated.

UCL’s findings indicate a T cell ‘growth factor’ (L-2) and a ‘transcription factor’ (Blimp-1) trigger the CD4+ T cell changes that enable them to engage with cancerous cells, thus indicating a possible activation mechanism.

The research, funded by Cancer Research UK, is just one of many promising new developments in this field. With growing knowledge and technological advancements, scientific research and medical studies that pay are becoming increasingly important. It’s all part of a bigger cause.

Image Credit

The Cell Basics

Lymphocytes (white blood cells) are constructed of different subsets of cells, including regulatory, cytotoxic and helper T cells. T cells are remarkably important for adaptive immune system responses in humans. They play various functions, from assisting B cells in destroying microbes to assisting cytotoxic T cell activation for killing infected cells. Immunotherapy therefore works by modifying T cells to attack cancerous cells.

Paving the Way for Future Advancements

T cells are typically unable to differentiate between cancerous and normal cells, so the challenge is to develop a way of correctly directing T cell activity in targeted immunotherapy. There are medical studies that pay where individuals can be part of such revolutionary innovations; Trials4us offer medical studies that pay and contribute to the exciting medical advances of tomorrow.

Professor Sergio Quezada, the co-lead author, notes that their study supports the use of Blimp-1 in maximising the CD4+ T cell tumour-attacking activity. The next steps include developing personalised therapies to activate helper cells to their full potential.

More research is required to utilise and develop these findings, but they could just hold the key to targeted therapies for cancer tumour destruction.